Roumell Asset Management, LLC Aridis Pharmaceuticals, Inc. Transaction History

Roumell Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	BUY	$2.0 - $3.65 $198,142 - $361,609	99,071 Added 28.51%	446,588 $1.04 Million
Q3 2021 Nov 12, 2021	BUY	$3.55 - $7.49 $264,940 - $558,986	74,631 Added 27.35%	347,517 $1.28 Million
Q2 2021 Aug 13, 2021	BUY	$5.3 - $7.4 $268,519 - $374,913	50,664 Added 22.8%	272,886 $2.02 Million
Q1 2021 May 14, 2021	BUY	$5.54 - $8.1 $1.23 Million - $1.8 Million	222,222 New	222,222 $1.31 Million

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Roumell Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Roumell Asset Management, LLC with notifications on news.